Catalog Products » HPN, His, Human
Manual
Manual
COAs

HPN, His, Human

Home parenteral nutrition (HPN) has been proposed as the treatment of choice in patients suffering from intestinal failure (IF) and has been claimed to improve survival and quality of life either in patients with benign disorders or even in those with malignancies. HPN seems to have beneficial effect but it should be considered with caution by the physicians who should take into account the indications of each patient to receive parenteral nutrition, the underlying disease and prognosis and the access of each patient to home care services.
$370.00
Z05381-100

Ask us a question
Product Introduction
Species Human
Protein Construction
HPN (Arg45-Leu417)
Accession # P05981		 His
N-term C-term
Purity > 95% as determined by Bis­Tris PAGE 
Endotoxin Level Less than 1EU per μg by the LAL method.
Biological Activity Measured by its binding ability in a functional ELISA. Test result was comparable to standard batch.
Expression System HEK293
Theoretical Molecular Weight 42 kDa
Apparent Molecular Weight Due to the protein cleaved into the following two chains, so it migrates to 18-22 kDa and 30 kDa based on Bis-Tris PAGE result.
Formulation Lyophilized from 0.22μm filtered solution in 20mM NaAc,150mM NaCl (pH 5.0).
Reconstitution Centrifuge the tube before opening. Reconstituting to a concentration more than 100 μg/ml is recommended. Dissolve the lyophilized protein in 20mM NaAc,150mM NaCl (pH 5.0).
Storage & Stability Upon receiving, the product remains stable for 6 months at -20℃ or below. Upon reconstitution, the product should be stable for 3 months at -80℃. Avoid repeated freeze-thaw cycles.
Back

HPN, His, Human

Immobilized HPN, His, Human, His Tag at 2 μg/ml (100 μI/well) on the plate. Dose response curve for Anti-HPN Antibody, hFc Tag with the EC50 of 9.3ng/ml determined by ELISA. »

HPN, His, Human

The purity of HPN, His, Human is greater than 95% as determined by SEC-HPLC. »

HPN, His, Human

HPN, His, Human on Bis-Tris PAGE under reduced condition. The purity is greater than 95%. »

<
>

Background
Target Background Home parenteral nutrition (HPN) has been proposed as the treatment of choice in patients suffering from intestinal failure (IF) and has been claimed to improve survival and quality of life either in patients with benign disorders or even in those with malignancies. HPN seems to have beneficial effect but it should be considered with caution by the physicians who should take into account the indications of each patient to receive parenteral nutrition, the underlying disease and prognosis and the access of each patient to home care services.
Synonyms Serine protease hepsin; TMPRSS1; Hepsin
Back

For research use only. Not intended for human or animal clinical trials, therapeutic or diagnostic use.